Alzheimer Disease

Memory Pharmaceuticals Reports First Quarter 2007 Financial Results

Published in Healthcare Mergers, Acquisitions and Ventures Week, May 26th, 2007

Memory Pharmaceuticals Corp. (NASDAQ:MEMY), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system (CNS) conditions, reported its financial results for the three months ended March 31, 2007.

"Our clinical objectives for 2007 include the completion of our ongoing proof-of-concept trials for MEM 1003 and MEM 3454, and we've made good progress during the first quarter of 2007 toward achieving these objectives," said Jim Sulat, President and Chief Executive Officer. "Since the beginning of the year, we've initiated our Phase 2a Alzheimer's disease trial for MEM 3454, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2007-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry